Public Release: 

Insilico to present at the 2nd Annual Artificial Intelligence and Blockchain in Healthcare Forum

Insilico Medicine to present and co-organize the 2nd Annual Artificial Intelligence And Blockchain In Healthcare at Basel Life Congress, Sept. 13-14, 2018, Basel, Switzerland

InSilico Medicine, Inc.


IMAGE: Alex Zhavoronkov, CEO of Insilico Medicine Inc., will present at the 2nd Annual Artificial Intelligence And Blockchain In Healthcare, during the Basel Life Congress, Sept. 13-14, 2018, Basel, Switzerland.... view more 

Credit: Insilico Medicine

Friday, August 3, 2018, Rockville, MD - Insilico Medicine, a Rockville-based company specializing in the application of next-generation artificial intelligence for drug discovery, biomarker development and aging research, announces the presentation of its CEO, Alex Zhavoronkov at 2nd Annual Artificial Intelligence And Blockchain In Healthcare Forum, during the Basel Life Congress, September 13-14, 2018, Basel, Switzerland.

Dr. Zhavoronkov will give a talk titled "Deep-learned Multi-modal Biomarkers of Aging" covering the latest advances in the applications of deep-learning technology to aging at the AI and Blockchain in Healthcare Forum.

"We are very happy to present our work and co-organize the 2nd Annual Artificial Intelligence And Blockchain In Healthcare Forum, during the Basel Life Congress, which gathers the thought leaders in Artificial Intelligence and Blockchain In Healthcare", said Alex Zhavoronkov, PhD, the founder and CEO of Insilico Medicine, Inc."

Artificial Intelligence and Blockchain for Aging Research and Drug Discovery is turning into a credible industry. One of the leading companies in the industry, Insilico Medicine received a recognition from the world's most prominent industry analysts including Frost & Sullivan and CB Insights.

2nd Artificial Intelligence and Blockchain in Healthcare innovation forum is an annual event at the EMBO/Basel Life Conference that brings together the key experts in AI and Blockchain to discuss the latest advances of these technologies in biopharmaceutical and healthcare sectors. This year the Forum is chaired by Alex Zhavoronkov, CEO at Insilico Medicine, and Verner De Biasi, Head Digital, Data and Analytics, PTS, GSK R&D. The event will be held in Basel on September 13-14, 2018.


Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. The paper published in Molecular Pharmaceutics in 2016 demonstrated the first proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. One of the latest paper published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients.

For further information, images or interviews, please contact:

Contact: Qingsong Zhu, PhD

Official Forum Website:

About Insilico Medicine, Inc

Insilico Medicine is an artificial intelligence company headquartered at in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan and Korea sourced through hackathons and competitions. The company and its scientists is dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine and aging research.

Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video:

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.